Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2022, vol. 31, nr 8, August, p. 913–925

doi: 10.17219/acem/147666

Publication type: review

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Cite as:

Konieczny RA, Kuliczkowski W. Trimethylamine N-oxide in cardiovascular disease. Adv Clin Exp Med. 2022;31(8):913–925. doi:10.17219/acem/147666

Trimethylamine N-oxide in cardiovascular disease

Radosław Andrzej Konieczny1,A,B,C,D, Wiktor Kuliczkowski2,C,E,F

1 Clinical Department of Gastroentrology and Hepatology, Wroclaw Medical University, Poland

2 Institute for Heart Diseases, Wroclaw Medical University, Poland


Although traditional cardiovascular risk factors are well established and understood, mortality and morbidity in patients with cardiovascular disease (CVD) remains high. Exploring new pathophysiological pathways enables a better understanding of CVD at both the molecular and clinical levels. Gut microbiota as a potential modulator of CVD are the subject of extensive research. In recent years, trimethylamine N-oxide (TMAO), a biologically active molecule generated by the gut microbiota, has been widely tested in studies on various populations of patients. The ultimate TMAO levels depend on individual features and gut microbiota composition. Most of the research on TMAO has focused on atherosclerotic CVD and heart failure (HF). Studies conducted so far support the use of TMAO as a prognostic marker in CVD. Several studies describe diverse interventions aimed at reducing the concentration of TMAO and its harmful effects. This article summarizes the findings from research, discusses the major insights into TMAO metabolism and related pathophysiological processes, as well as indicates the directions for future research.

Key words: gut microbiota, coronary artery disease, heart failure, TMAO, trimethylamine oxide



According to the World Health Organization (WHO), cardiovascular disease (CVD) remains the major cause of death and disability worldwide.1 Exploring new pathophysiological pathways enables a better understanding of CVD at both the molecular and clinical levels. Owing to the development of metabolomics and metagenomics, the intestinal microbiota have been indicated as a potential modulator of the course of CVD. Trimethylamine N-oxide (TMAO) is a gut-derived metabolite whose usefulness has been evaluated in numerous studies. Despite promising results, TMAO is an example of a deeply researched gut microbiome biomarker which is still not used in everyday clinical practice. In order to determine the utility of a new biomarker, it is first necessary to assess its metabolism and related pathophysiological processes, followed by clinical trials.2 This review summarizes extensive literature on TMAO and indicates gaps in knowledge existing after more than 10 years of research.


The purpose of this article was to provide an overview of the metabolism of TMAO and associated pathophysiological processes, and the results of major studies. An attempt was also made to indicate the direction of further research.


Literature search was carried out in the PubMed database on November 3, 2021 using the queries: “(TMAO) AND (atherosclerosis)”, “(TMAO) AND (coronary artery disease)”, “(TMAO) AND (atrial fibrillation)”, “(TMAO) AND (heart failure)”, and “(TMAO) AND (gut microbiota)”. Selected key studies concern diverse groups of patients with CVD. Their results are discussed in the text and presented in tables below.

Metabolism of TMAO

The TMAO is an organic compound with the chemical formula of (CH3)3NO. It is commonly found in the tissues of marine organisms, where it mitigates the adverse effects of temperature, salinity, as well as high urea and hydrostatic pressure.3 In humans, TMAO is produced by the oxidation of trimethylamine (TMA) and is absorbed directly from food. The TMAO is most abundant in fish and seafood.4 Gut microbiota produce TMA from the dietary precursors: choline, L-carnitine, and betaine. These TMA precursors are most abundant in red meat and eggs.5 The most recent research indicates that the intake of foods rich in TMA precursors does not translate directly into an increase in plasma TMAO level because it depends on individual metabolic features, such as hepatic enzymes activity and gut microbiota composition.6, 7

Carnitine metabolism is key to human TMAO production and 3 major bacterial metabolic pathways leading to TMA synthesis from dietary precursors were described8:

a) anaerobic choline degradation by choline TMA-lyase;

b) hydroxylation of L-carnitine to TMA by carnitine oxidoreductase; and

c) conversion of L-carnitine to γ-butyrobetaine, which is then converted to TMA.

Trimethylamine produced by gut microbiota is excreted from the gut via 3 mechanisms: it can be absorbed to the circulation, excreted with stool or used by other bacteria in the process of syntrophy. Trimethylamine that has been absorbed to the circulation is oxidized to TMAO by hepatic flavin-containing monooxygenase (FMO).5 Trimethylamine absorption occurs in the small intestine (Figure 1).9 After absorption, TMA is almost immediately oxidized to TMAO. Following the oral intake of phosphatidylcholine, the highest plasma and urinary TMAO levels are observed after 12 h and 24 h, respectively. After 48 h from intake, the plasma TMAO level returns to baseline.9 The TMAO taken with food is absorbed through the intestinal barrier and is detectable in blood after 15 min. The maximum blood concentration is reached after 1 h and is maintained for approx. 6 h. After 24 h, 96% of the TMAO dose taken with food is excreted with urine, mostly in an unchanged form.10

To determine the concentration of TMAO, liquid chromatography coupled with tandem mass spectrometry and automated nuclear magnetic resonance spectrometry are most often used.4 Due to the need of specialized equipment, reliable TMAO determination is possible in research or academic facilities; however, mentioned methods become more available.

The effect of TMAO on pathophysiological processes

The first studies reporting the negative effects of TMAO were conducted on an animal model and focused on atherogenesis. Initially, it was determined that TMAO accelerates the production of foam cells from macrophages. The TMAO was shown to promote the upregulation of the scavenger receptors CD36 and SR-A111 as well as induce inflammation12 via the MAPK/JNP pathway, which regulates the synthesis of pro-inflammatory cytokines – tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6) and intercellular adhesion molecule 1 (ICAM-1). This leads to cholesterol overload in macrophage foam cells and their faster migration and adhesion to endothelial cells. A study on human umbilical vein endothelial cells (HUVECs) confirmed a link between high plasma TMAO levels and the development of atherosclerosis. Moreover, it indicated that TMAO impaired endothelial self-repair already in the early stages of atherogenesis.13 This is due to the inhibitory effect of TMAO on endothelial cell proliferation during the G0/G1 phase of the cell cycle14 as well as its cytotoxic effect on circulating endothelial progenitor cells.15 This cascade of events is accompanied by increased oxidative stress, another postulated effect of chronically elevated TMAO levels, observed also in healthy individuals.16 The effect of TMAO on pathophysiological processes is depicted in Figure 2.

At a systemic level, TMAO promotes atherogenesis by altering lipid metabolism. In a study on a mice model, Koeth et al. demonstrated that TMAO inhibited the expression of the Cyp7a1 enzyme and bile acid transport proteins.17 The Cyp7a1 is responsible for bile acid synthesis and inhibition of cholesterol catabolism. The lack of Cyp7a1 leads to the reduced bile acid synthesis and secretion, resulting in atherosclerosis progression. At the same time, a reduction in the expression of bile acid transporter proteins in the liver negatively affects the major pathway of elimination of cholesterol from the body.17

Along with research on atherosclerosis, there have been studies investigating the prothrombotic effect of TMAO. Impaired intracellular calcium ion transport in platelets, heightened platelet reactivity and increased platelet adhesion to collagen fibers were reported.18 In endothelial cells, an increased tissue factor synthesis and downregulation of thrombomodulin were described.19

Direct cardiotoxic and proarrhythmic effects of TMAO

The cardiotoxicity of TMAO was confirmed in morphological and functional studies, mainly in animal models. By activating the inflammatory pathways, TMAO promotes cardiac fibrosis, heart weight gain and cardiac remodeling.20 At a cellular level, TMAO impairs the intracellular microtubule network and alters calcium concentration control in cardiac muscle cells. This leads to a decrease in contraction amplitude, longer time of peak and reduced synchronization.21 Similar TMAO-induced abnormalities in contractility were also reported in ex-vivo human cardiac tissue.22

Results from studies on TMAO

Over the past 10 years, numerous studies investigating the prognostic value of TMAO have been conducted. The research included various populations of patients, both with acute and chronic illness. Most of those studies enrolled patients with coronary artery disease (CAD) and heart failure (HF). Selected studies are discussed below and summarized in Table 1.

The first meaningful study on the effect of TMAO in CAD was published in 2013.23 Tang et al. demonstrated that higher plasma TMAO levels correlated with an increased risk of major adverse cardiovascular events (MACEs) during a 3-year follow-up in 4007 patients referred for elective coronary angiography.23 The correlation was revealed even after adjustment for traditional risk factors. Similar findings were reported by Senthong et al. in a study of 2235 patients with significant coronary artery stenosis receiving optimal treatment. Higher TMAO levels predicted mortality independent of traditional risk factors during a 5-year follow-up.24 In a longitudinal study by Lee et al.,25 a significant association between higher levels of TMAO and increased risk of incident and recurrent atherosclerotic CVD was shown.25 Another large community-based study of middle-aged participants revealed that higher TMAO levels are associated with the risk of CAD in previously healthy individuals.26

The prognostic value of TMAO was also assessed in patients with acute coronary syndrome (ACS). Increased TMAO levels showed an association with the risk of death or recurrent myocardial infarction (MI) during a 2-year follow-up,27 as well as with future cardiovascular events during a 5-year follow-up.28 Importantly, the risk persisted despite the improvement regarding traditional cardiovascular risk factors such as hypertension, dyslipidemia or diabetes.28 In another interesting study, Li et al. showed that increased TMAO levels were a risk factor for MACEs at 30 days and 6 months in patients presenting with chest pain of suspected cardiac origin.29 The strong prognostic significance of TMAO was observed irrespective of baseline troponin levels and the final diagnosis of ACS. In the same study, in an independent cohort of patients with ACS who underwent coronary angiography due to ACS, higher TMAO levels were associated with an increased risk of MACEs at 1 year, independent of traditional risk factors.

In addition to predicting future MACEs, plasma TMAO levels were shown to correlate with the extent of CAD and atherosclerotic plaque stability. Studies conducted to date have revealed an association between TMAO levels and the SYNTAX Score, multivessel CAD30, 31 and the risk of atherosclerotic plaque rupture.32, 33 Finally, it was reported that TMAO could act as a mediator of clopidogrel resistance and inhibit clopidogrel effects, which has significant implications for the medical treatment of CAD.34

In the context of atherosclerosis, TMAO has also been investigated in patients with chronic kidney disease (CKD).35, 36 As renal function deteriorates, TMAO level increases and correlates with coronary atherosclerosis burden,35 gut microbiota alterations, increased intestinal permeability, chronic inflammation, and endothelial dysfunction.36 Chronic kidney disease has complex pathogenesis and dynamics. The higher risk of death and the extent of atherosclerosis are therefore the cumulative effect of many processes. Accordingly, TMAO is one of the bystanders rather than the single and direct causative agent of vascular complications of CKD.

Heart failure

There is a considerable body of evidence on the role of TMAO as a prognostic marker in patients with HF. These associations were studied in the chronic and acute settings as well as depending on the preserved or reduced ejection fraction and the burden of symptoms.

A significant association between increased TMAO levels and mortality risk in patients with chronic HF (CHF) was first described in 2014.37 Subsequent studies reported associations with the New York Heart Association (NYHA) functional class and CHF after MI.38, 39 Schuett et al. demonstrated that increased TMAO levels were a strong predictor of mortality in patients with HF with reduced ejection fraction, but not in those with preserved ejection fraction, over a mean follow-up of 9.7 years.40

Several studies reported data on the effect of increased TMAO levels on disease course and prognosis in patients with acute HF. Suzuki et al. showed that elevated TMAO levels were a strong predictor of mortality or rehospitalization at 1 year.41 However, after adjustment for renal confounders, the correlation was no longer significant,41 which is in line with the results of a more recent study by Israr et al.42 In a multicenter study including patients with new-onset or progressive HF, higher TMAO levels were strongly associated with an increased risk of mortality and/or rehospitalization during 1-, 2- and 3-year follow-up. In line with previous studies, TMAO levels were not reduced by optimal treatment.43

The association between elevated TMAO levels and poor prognosis in patients with HF has not been fully elucidated so far. Apart from gut microbiota, the role of FMO3 polymorphism has been postulated.44 Moreover, Li et al. suggested a potential inhibitory effect of loop diuretics on renal excretion of TMAO, resulting in its retention in tissues.45

Atrial fibrillation

The role of TMAO as a risk factor or mediator of atrial fibrillation (AF) has not been determined so far.46 A study on 2 Norwegian cohorts indicated that high TMAO levels were associated with a risk of incident AF, independent of traditional risk factors.47 In the AF-RISK study, higher TMAO levels were associated with progression to permanent AF.48 Finally, the proarrhythmic and prothrombotic effects of TMAO can result in increased risk of thrombus formation in patients with AF.49

Results from meta-analyses

There are several meta-analyses assessing TMAO levels as a predictor of mortality or other adverse events in patients with CVD.50, 51, 52, 53, 54, 55 The results strongly indicate that elevated TMAO levels are a significant risk factor for death and MACEs. Selected meta-analyses are summarized in Table 2.

Interventions aimed at reducing TMAO levels and toxicity

The knowledge of TMAO synthesis, metabolism and excretion pathways allows investigators to study interventions aimed at reducing TMAO toxicity. Some of the conclusions were formulated on the basis of random findings derived from other studies. Examples include the association between statin use and reduced TMAO levels56 or between aspirin use and reduced TMA synthesis.57 In both cases, the lowering effect was probably due to drug-induced alterations in gut microbiota.

A standard targeted approach is to reduce the dietary intake of TMA precursors and TMAO. The elimination of red meat from diet results in reduced TMAO levels after 4 weeks,5 while vegetarians and vegans have lower circulating TMAO levels and a lower capacity to synthesize TMA, probably due to changes in gut microbiota.17 The beneficial effect of Mediterranean diet on reducing TMAO levels is primarily due to the high intake of plant foods,58 although the results of studies are equivocal.59

The use of broad-spectrum antibiotics was shown to suppress gut microbiota and reduce TMAO levels. However, antibiotic therapy does not offer satisfactory long-term outcomes and is associated with a high risk of side effects.11 Rifaximin has been reported to be a safer alternative, but the results of the recent GUTHEART study are insufficient to confirm this suggestion.60 Other interventions include supplementation with probiotics,61 gut bacteria transplant from healthy donors,62 bariatric surgery,63 resveratrol,64 and meldonium.65 Current interventions are summarized in Table 3 and Figure 3.

Review limitations and gaps in knowledge

The possibility of discussing all ongoing studies in microbiota biomarkers is beyond the scope of this review. For now, to the best of our knowledge, despite the extensive literature supporting its usefulness, TMAO has not been identified as an established biomarker in CAD or HF guidelines. Perhaps, the ongoing research will consolidate the use of TMAO and other gut microbiota metabolites such as bile acids and short chain fatty acids in everyday practice. Linking the metabolism of the gut microbiota to CVD is an attractive topic of ongoing research. It is worth mentioning the studies NCT0496276366 and NCT02728154,67 which will deepen the knowledge on the correlation of the intestinal microbiota with HF. The study NCT05014880 is going to assess the effectiveness of a dietary intervention reducing dietary TMAO levels during the rehabilitation of CAD patients.68


The TMAO is a biomarker that has been proven useful in a population of patients at higher cardiovascular risk. The use of TMAO in clinical practice requires confirmation in subsequent prospective interventional studies.


Table 1. Results of studies on the association of TMAO with cardiovascular risk


Type of study

Population characteristics


Study endpoint


HR/OR (95% CI)



median (IQR)

Coronary artery disease

Tang et al.23

prospective study

n = 4007; patients undergoing elective coronary angiography


age: 63 ±11

male sex: 64%

3 years


(death, myocardial infarction, stroke)

TMAO Q4 compared to Q1

MACE n = 513,

HR 2.54 [1.96; 3.28]; p < 0.001

multivariate HR 1.43 [1.05; 1.94]

death HR 3.37 [2.39; 4.75]; p < 0.001

nonfatal myocardial infarction or stroke HR 2.13 [1.48; 3.05]; p < 0.001

3.7 (2.4–6.20)

MACE 5.0 (3.0–8.8)


3.5 μM (2.4–5.9); p < 0.001

Senthong et al.24

prospective study

n = 2235; patients with stable coronary artery disease who underwent elective coronary angiography


age: 63 ±11 years

male sex: 71%

5 years

death (all-cause)

TMAO Q4 compared to Q1

death n = 338

HR 3.90 [2.78; 5.48]; p < 0.0001

3.8 (2.5–6.5)

Q4 > 6.5; 9.7 (7.7–14.9)

Lee et al.25

prospective multicenter community-based cohort study

n = 5580


age: 72 ±5.3 years

male sex: 36%

a) participants free of prevalent cardiovascular disease (n = 4131)

age: 72.2 ±5.3 years

male sex: 36%

b) participants with prevalent cardiovascular disease (n = 1449)

age: 73.6 ±5.8 years

male sex = 53%

15 years

ASCVD defined as MI (fatal and nonfatal), fatal coronary heart disease, stroke (fatal and nonfatal), sudden cardiac death, and other atherosclerotic death

quintile 5 compared to quintile 1

multivariable HR 1.23 [1.04; 1.45]; p = 0.028

multivariable, diet and renal function adjusted HR 1.08 [0.91; 1.29]; p = 0.579

a) multivariable, diet and continuous eGFR, adjusted HR 1.07 [0.90; 1.27]; p = 0.516

b) multivariable HR 1.25 [1.01; 1.56]; p = 0.009

multivariable, diet and continuous eGFR, HR 1.10 [0.87; 1.39]; p = 0.179

4.7 (3.2–7.7)

quintile 1 = 2.29 (1.84–2.61)

quintile 5 = 13.2 (10.4–19.9)

a) 4.72 (3.19–7.69)

eGFR 70.1 (16.2)

b) 5.43 (3.57–8.74)

eGFR 63.8 (17.9)

Tang et al.26

nested case-control study

n = 2181; healthy individuals


age: 65 ±8 years

male sex: 65%

8 years

CAD – hospital admission and/or death with CAD as underlying cause (ICD9 Code 410–414)

Q4 compared to Q1

n = 908

OR 1.86 [1.46; 2.37]; p < 0.001

adjusted for traditional risk factors OR 1.58 [1.21; 2.06]; p < 0.001

3.4 (2.3–5.7)

Suzuki et al.27

retrospective study

n = 1079; acute MI patients


age: 67 (57–77) years

male sex: 72%

2 years

all-cause mortality


TMAO T3 compared to T1

n = 292 events

all-cause mortality n = 119

HR 1.21 [0.98; 1.48]

p = 0.074

death/MI n = 232

HR 1.40 [1.26; 1.55]

p < 0.0005

multivariate HR 1.21 [1.03; 1.4] p = 0.023

3.7 (4.6–6.4)

T3 > 5.1; 8.5 (6.2–15.0)

Matsuzawa et al.28

observational study

n = 112; STEMI patients who underwent primary PCI


age: 63 (56–71) years

male sex: 88%

median: 5.4 years

cardiovascular events

death n = 5

nonfatal myocardial infarction n = 5,

unstable angina requiring revascularization n = 2

nonfatal stroke n = 5

TMAO >6.76 compared to <6.76

adjusted HR 6.21 [1.69; 30.285]; p = 0.005

adjusted HR for 0.1 increase in log TMAO 1.343 [1.122; 1.636]; p = 0.001

6.76 (3.82–12.53)

Li et al.29

prospective study

n = 530; patients presenting to the emergency department with chest pain of suspected cardiac origin (112 troponin T-positive)


age: 62.4 ±13.9 years

male sex: 57.5%

n = 1683 who underwent coronary angiography for ACS


age: 63.9 ±12.4 years

male sex: 77.8%

1 month, 6 months, 7 years,

1 year

MACE defined as a composite of MI, stroke, revascularization, or all-cause mortality (1 month, 6 months),

all-cause mortality (7 years)

TMAO Q4 compared to Q1

MACE 1 month OR 6.30 [1.89; 21.0]; p < 0.01

MACE 6 months n = 220 (death n = 29)

OR 5.65 [1.91; 16.7]; p < 0.01

mortality 7 years HR 1.81 [1.04; 3.15]; p < 0.05

MACE n = 119 (death n = 79) (1 year Q4 HR 1.57 [1.03; 2.41]; p < 0.05

4.28 (2.55–7.91)

2.87 (1.94–4.85)

Sheng et al.30

prospective observational study

n = 335; patients with STEMI


age: 58.7 ±12.1 years

male sex: 80.6%


SYNTAX Score ≥23

presence of multivessel disease

adjusted OR 1.16 [1.06; 1.29]; p = 0.001

r = 0.237, p < 0.001

AUC 0.656 [0.591; 0.722]; p < 0.001

adjusted OR 1.15 [1.01; 1.32]; p = 0.035

r = 0.192, p < 0.001

2.18 (1.34–3.90)

Senthong et al.31

prospective cohort study

n = 353; stable patients with CAD detected by elective coronary angiography


age: 65.0 ±11.0 years

male sex: 79%




presence of diffuse lesions

SYNTAX Score (r = 0.61) p < 0.0001

adjusted OR 4.82; p < 0.0001

SYNTAX Score II (r = 0.62) p < 0.0001

adjusted OR = 1.88; p = 0.0001

8.4 [5.7; 14.0] compared to 4.4 [5.2; 13.5]

adjusted OR 2.05 [1.45; 2.90], p = 0.0001

5.5 mM (3.4–9.8)

Fu et al.32

observational study

n = 26 patients with CAD who underwent optical coherence tomography


age: 60 ±10 years

male sex: 77%

n = 12 – plaque rupture group

n = 14 – non-plaque rupture group


TMAO concentration in rupture compared to non-rupture TMAO concentration and plaque composition

TMAO level – lipid arc (r = 0.43, p = 0.031),

lipid volume index (r = 0.39, p = 0.048)

rupture compared to no rupture

8.6 ±4.8 compared to 4.2 ±2.4; p = 0.011

Tan et al.33

prospective observational study

n = 146; STEMI with pre-intervention optical coherence tomography


age: 57.0 ±11.0 years

male sex: 82.2%

n = 77 – plaque rupture

n = 69 – plaque erosion



rupture compared to erosion

rupture adjusted OR 4.06 [2.38; 6.91]; p < 0.001

AUROC 0.89,

1.95 μM sensitivity = 88.3%, specificity = 76.8%

rupture compared to erosion 3.33 (2.48–4.57) compared to 1.21 (0.86–1.91); p < 0.001

Heart failure

Tang et al.37

single-center prospective cohort study

n = 720; stable subjects with HF, patients with ACS within the preceding 30 days excluded


age: 66 ±10 years

male sex: 59%

5 years

all-cause mortality

death n = 207

Q4 compared to Q1

adjusted for traditional risk factors and BNP HR 2.2 [1.42; 3.43]; p < 0.001

adjusted for renal function HR 1.75 [1.07; 2.86]; p < 0.001

5.0 (3.0–8.5)

Trøseid et al.38

prospective observational study

n = 155; patients with stable HF for >6 months (NYHA class II–IV)


age: 57 ±11 years

male sex: 83%

n = 73 – CAD

n = 75 – DCM

n = 7 – other

median: 5.2 years

all-cause and

anticipated mortality, i.e., HTx

death (n = 39)

HTx (n = 16)

T3 compared to T1 unadjusted HR 2.24 [1.28; 3.92]; p = 0.005

adjusted HR 1.79 [0.90; 1.79]; p = 0.097

NYHA class II/III/IV r = 0.15, p < 0.05

CAD – 12.1 ±19.5

DCM – 9.2 ±8.5

healthy control – 7.9 ±8.9

Zhou et al.39

prospective cohort study

n = 1208; patients with chronic HF after MI


age: 73 (64–80) years

male sex: 68.5%

median: 1.84 years

MACE, all-cause mortality, HF rehospitalization, recurrent MI

all-cause mortality

Q4 compared to Q1

MACE n = 507

death n = 56

readmitted with HF n = 384

recurrent MI n = 67

unadjusted HR 3.15 [2.09; 4.73]; p < 0.01

adjusted HR 2.31 [1.42; 3.59]; p < 0.01

all-cause mortality HR 2.15 [1.37; 3.24]; p < 0.01

Q4 > 7.92

Q1 < 2.83

Schuett et al.40

retrospective study

n = 2490; LURIC population


n = 823 – HF patients:

HFrEF (n = 428) and HFpEF (n = 395)

mean: 9.7 years

all-cause mortality

death due to cardiovascular causes

all patients

T3 compared to T1

death n = 728

1.70 [1.41; 2.04]; p < 0.001

cardiovascular death n = 446

1.87 [1.48; 2.38]


T3 compared to T1

death 2.33 [1.67; 3.24]; p < 0.001

cardiovascular death 2.27 [1.52; 3.37]

HFpEF – ns

T3 ≥ 5.92

T1 ≤ 3.90

Suzuki et al.41

retrospective study

n = 972; patients with acute HF


age: 78 (69–84) years

male sex: 61%

1 year

all-cause mortality (death)

composite death or rehospitalization due to HF (death/HF)

death n = 268

T3 compared to T1

univariate HR 1.35 [1.21; 1.51]; p < 0.0005

n = 384

death/HF HR 1.33 [1.20; 1.46]; p < 0.0005

adjusted for renal function – ns

5.6 (3.4–10.5)

T3 = 14.2 (8.2–151.5)

T1 = 2.9 (0.5–4.0)

Israr et al.42

retrospective study

n = 806; patients with acute HF


age: 78 (69–84) years

male sex: 61%

1 year

death at 30 days n = 62

death at 1 year n = 213

death/HF at 30 days n = 98

death/HF at 1 year n = 313

T3 compared to T1

HR 1.39 [1.05; 1.84]; p = 0.022

HR 1.26 [1.08; 1.47] p = 0.004

HR 1.38 [1.10; 1.73] p = 0.006

HR 1.25 [1.09; 1.42] p = 0.001

adjusted for renal function – ns

10.2 (5.8–18.7)

Suzuki et al.43

multicenter prospective study (BIOSTAT-CHF)

n = 2234; patients with progressive worsening or new-onset symptoms of HF


age: 70 (61–78) years

male sex: 74%

3 years

all-cause mortality (3 years)

composite event of mortality combined with rehospitalization due to HF (3 years)

unadjusted HR 2.27 [1.90; 2.72]; p < 0.001

adjusted |HR 1.42 [1.13; 1.80];

p = 0.003

unadjusted HR 1.93 [1.66; 2.23]; p < 0.001

adjusted HR

1.21 [1.00; 1.46]; p = 0.054

5.9 (3.6–10.8)

Wei et al.44

prospective study

n = 915; chronic HF patients with reduced ejection fraction


age: 57.1 ±14.1 years

male sex: 69.9%

median: 33 months, max. 7 years

cardiovascular death or HTx (n = 314)

recurrence of HF + first rehospitalization for cardiovascular causes

T3 compared to T1

HR 1.47 [1.13; 1.91]; p = 0.004

adjusted HR 1.33 [1.01; 1.74]; p = 0.039

high dose-dependent association: first rehospitalization for cardiovascular causes (p = 0.002)

recurrence of HF (p = 0.003)

2.52 (1.20–4.76)

T3 > 3.770

T1 ≤ 1.574

Atrial fibrillation

Svingen et al.47

retrospective cohort study

n = 3797; patients with suspected stable angina Europe

n = 3143; community-based control population Europe

median: 7.3 years

community control 10.8 years

diagnosis of AF during hospitalization

m = 412

Q4 compared to Q1

adjusted HR 1.16 [1.05; 1.28]; p = 0.0009

community control n = 484

adjusted HR 1.10 [1.004; 1.19] per 1 standard deviation increase in log-transformed plasma TMAO

Q4 > 15.8 (11.9–23.5)

Q1 < 2.7 (2.2–3.2)

Gong et al.49

prospective observational cohort study

n = 117; consecutive rheumatic heart disease patients with AF

age: 57 (50–64) years

male sex: 41%

n = 25 – patients with cardiac thrombi

n = 92 – patients without cardiac thrombi


comparison of TMAO concentration between 2 groups

TMAO, group I compared to group II: 4.55 [3.19; 4.83] compared to
3.53 [2.96; 4.25]; p = 0.01


ACS – acute coronary syndrome; DCM – dilated cardiomyopathy; MACE – major adverse cardiac event; TMAO – trimethylamine oxide; a – age; m – male; Q – quartile; T – tertile; HR – hazard ratio; OR – odds ratio; 95% CI – 95% confidence interval; IQR – interquartile range; AUROC – area under the receiver operating characteristic curve; ASCVD – atherosclerotic cardiovascular disease; CAD – coronary artery disease; MI – myocardial infarction; HF – heart failure; HFrEF – heart failure with reduced ejection fraction; HFpEF – heart failure with preserved ejection fraction; BNP – brain natriuretic peptide; HTx – heart transplantation; LURIC – Ludwigshafen Risk and Cardiovascular Health; PCI – percutaneous coronary intervention; SYNTAX – synergy between percutaneous coronary intervention with taxus and cardiac surgery score; STEMI – ST-segment elevation myocardial infarction; NYHA – New York Heart Association; eGFR – estimated glomerular filtration rate; N/A – not available/not applicable; AUC – area under the curve; AF – atrial fibrillation; N/A – not applicable; ns – nonsignificant.
Table 2. Results of meta-analyses on the association of TMAO with cardiovascular risk



(number of studies included)



RR/HR (95% CI)

Heianza et al.50

n = 19,256 (19)

MACCE, death

MACE: RR 1.62 [1.45; 1.80]; p < 0.001, I2 = 23.5%

death: RR 1.63 [1.36; 1.95]; I2 = 45.9%

Schiattarella et al.51

n = 26,167 (26)

MACCE, death

MACCE: RR 1.67 [1.33; 2.11]; p < 0.00001, I2 = 46%

death: RR 1.91 [1.40; 2.61]; p < 0.0001, I2 = 94%

Qi et al.52

n = 7716 (11)

cardiovascular events, death

cardiovascular events: RR 1.23 [1.07; 1.42]; I2 = 31.4%

death: RR 1.55 [1.19; 2.02]; I2 = 80.8%


n = 31,230 (20)


death: RR 1.466 [1.291; 1.665]; p < 0.001, I2 = 81.9%

Li et al.54

n = 6879 (7)

MACE, death

MACE: T3 compared to T1: HR 1.68 [1.44; 1.96]

death: T3 compared to T1: HR 1.67 [1.17; 2.38]

Guasti et al.55

n = 923 (3)

MACE, death

MACE: RR 2.05 [1.61; 2.61]; I2 = 50%

death: RR 3.42 [2.27; 5.15]; I2 = 0%

TMAO – trimethylamine oxide; MACE – major adverse cardiac events; MACCE – major adverse cardiac and cerebrovascular events; CVE – cardiovascular events; HR – hazard ratio; RR – risk ratio; T – tertile; CI – confidence interval.
Table 3. Results of studies assessing therapeutic strategies aimed at reducing TMAO levels


Type of study






Li et al.56

retrospective study; 3-year follow-up

n = 4007; sequential patients undergoing elective diagnostic coronary angiography

statin use

MACE, defined as death, myocardial infarction, or stroke;

reduction of TMAO concentration

n = 322 MACE by 3 years

statin use associated with decreased MACE: HR 0.74, 95% CI: [0.60; 0.93]; p = 0.0089

plasma TMAO associated with increased MACE: HR 1.57, 95% CI: [1.40; 1.76]; p = 2.4e-14

statin use associated with decreased TMAO (3.9 compared to 4.3) p = 0.002

suspected mechanism: alteration in gut microbiome activity

Zhu et al.57

prospective study

healthy vegans/vegetarians (n = 8); healthy omnivores (n = 10) orally supplemented with choline

aspirin 81 mg/day for 3 months

reduction of TMAO concentration

aspirin attenuated TMAO elevation


choline compared to choline + ASA 36.9 ±9.4 compared to 21.2 ±3.0; p = 0.009

suspected mechanism: alteration in gut microbiome activity

Wang et al.5

prospective study

n = 113; healthy adult participants

all omnivores

discontinuation of red meat intake to non-meat or white meat

reduction of TMAO concentration

no meat – TMAO reduction; p < 0.0001

white meat – TMAO reduction; p < 0.0001


Awoyemi et al.60

prospective randomized, double-blind study

n = 151; patients with LVEF < 40%; NYHA class II–III despite optimal medical therapy

3 months: rifaximin, 550 mg twice daily, 250 mg

3 months: probiotic Saccharomyces boulardii NCM I-745 500 mg twice daily

standard of care only

LVEF after 3 months of intervention

baseline-adjusted NT-proBNP

baseline-adjusted TMAO

LVEF: rifaximin compared to standard of care mean difference: −1.2 pp (3.2–0.7); p = 0.22

Saccharomyces boulardii −0.2 pp (2.2–1.9); p = 0.87

NT-proBNP: no significant effects rifaximin p = 0.28

S. boulardii: increase; p = 0.03

TMAO: no significant effects

rifaximin; p = 0.8

Saccharomyces boulardii p = 0.16

patients low in baseline dysbiosis

low dose of rifaximin

Boutagy et al.61

randomized double-blind, placebo-controlled

n = 19; healthy, non-obese males (18–30 years)

4-week hypercaloric (+1000 kcal day−1), high-fat diet (55% fat) +

VSL#3 (900 billion live bacteria) orally


reduction of TMAO concentration

plasma TMAO level increased significantly

VSL#3 (89 ±66%); p < 0.05

placebo (115 ±61%); p < 0.05

VSL#3 compared to placebo: p > 0.05

VSL#3 does not influence plasma TMAO following a high-fat diet

Smits et al.62

double-blind randomized pilot study

n = 20; male patients with metabolic syndrome

vegan-donor FMT

conversion of choline and carnitine to TMA and TMAO

fasting plasma TMAO level

TMA/TMAO urinary excretion

no signifficant effect; p > 0.05

significant changes in intestinal microbiota composition did not affect TMAO metabolism;

residual capacity to convert precursors to TMAO in vegans?

short follow-up (2 weeks)

Trøseid et al.63

observational study

n = 34; obese patients (17 with and 17 without type 2 diabetes) undergoing bariatric surgery

bariatric surgery

laparoscopic Roux-en-Y gastric bypass

duodenal switch

abseline plasma TMAO level

preoperatively (after 3 months of lifestyle intervention)

1 year after bariatric surgery

no significant effect of 3-month lifestyle intervention preoperatively; 1 year after bariatric surgery TMAO plasma levels more than doubled (HR 10.5, 95% CI: [7.5; 13.5]) compared to preoperative (HR 4.4, 95% CI: [2.8; 6.0]; p < 0.001) compared to baseline (HR 4.7, 95% CI: [3.7; 5.8]; p < 0.001), regardless of surgical method

mechanism: changes in gut microbiota profile

Annunziata et al.64

double-blind, randomized, placebo-controlled study

n = 380; healthy individuals

grape pomace polyphenol nutraceutical (rich in resveratrol) 400 mg twice daily 4 weeks, 8 weeks

reduction of TMAO concentration

plasma TMAO reduction (−49.78%, p < 0.0001)

8 weeks − 75.85%; p < 0.0001


Dambrova et al.65

open label, interventional study

n = 8; healthy volunteers

meldonium orally, 500 mg twice daily, 7 days during TMAO-rich diet

reduction of TMAO concentration

urine TMAO excretion

diet compared to diet + meldonium

plasma: 81.5 ±8.6 mM compared to 43.0 ±3.8 mM; p < 0.05

excretion: 18.2 ±2.2 mmol/mg creatinine × 7 days compared to 24.3 ±1.5 mmol/mg creatinine × 7 days;

p < 0.05


LVEF – left ventricular ejection fraction; MACE – major adverse cardiac event; N/A – not available/not applicable; NYHA – New York Heart Association functional classification; TMAO – trimethylamine oxide; NT-proBNP – N-terminal pro-B-type natriuretic peptide; FMT – fecal microbiota transplant; TMA – trimethylamine; ASA – acetylsalicylic acid (aspirin); HR – hazard ratio; 95% CI – 95% confidence interval.


Fig. 1. Schematic presentation of the intestinal absorption of TMA and TMAO
TMA – trimethylamine; TMAO – trimethylamine N-oxide; FMO – flavin-containing monooxygenase.
Fig. 2. Effect of TMAO on pathophysiological processes
TMAO – trimethylamine N-oxide; ASCVD – atherosclerotic cardiovascular disease; EPC – endothelial progenitor cells; HF – heart failure; MACE – major cardiovascular events; TF – tissue factor; TM – thrombomodulin.
Fig. 3. Therapeutic strategies affecting TMAO levels and metabolism in humans. Detailed information included in Table 3, with consistent reference numbers
TMAO – trimethylamine N-oxide.

References (68)

  1. Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organization and United Nations. Int J Cardiol. 2013;168(2):934–945. doi:10.1016/j.ijcard.2012.10.046
  2. Gambardella J, Castellanos V, Santulli G. Standardizing translational microbiome studies and metagenomic analyses. Cardiovasc Res. 2021;117(3):640–642. doi:10.1093/cvr/cvaa175
  3. Velasquez MT, Ramezani A, Manal A, Raj DS. Trimethylamine N-oxide: The good, the bad and the unknown. Toxins (Basel). 2016;8(11):326. doi:10.3390/toxins8110326
  4. Lombardo M, Aulisa G, Marcon D, et al. Association of urinary and plasma levels of trimethylamine N-oxide (TMAO) with foods. Nutrients. 2021;13(5):1426. doi:10.3390/nu13051426
  5. Wang Z, Bergeron N, Levison BS, et al. Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-oxide metabolism and renal excretion in healthy men and women. Eur Heart J. 2019;40(7):583–594. doi:10.1093/eurheartj/ehy799
  6. Hamaya R, Ivey KL, Lee DH, et al. Association of diet with circulating trimethylamine-N-oxide concentration. Am J Clin Nutr. 2020;112(6):1448–1455. doi:10.1093/ajcn/nqaa225
  7. Cho CE, Aardema NDJ, Bunnell ML, et al. Effect of choline forms and gut microbiota composition on trimethylamine-N-oxide response in healthy men. Nutrients. 2020;12(8):2220. doi:10.3390/nu12082220
  8. Janeiro MH, Ramírez MJ, Milagro FI, et al. Implication of trimethylamine N-oxide (TMAO) in disease: Potential biomarker or new therapeutic target. Nutrients. 2018;10(10):1398. doi:10.3390/nu10101398
  9. Stremmel W, Schmidt KV, Schuhmann V, et al. Blood trimethylamine-N-oxide originates from microbiota mediated breakdown of phosphatidylcholine and absorption from small intestine. PLoS One. 2017;12(1):e0170742. doi:10.1371/journal.pone.0170742
  10. Taesuwan S, Cho CE, Malysheva OV, et al. The metabolic fate of isotopically labeled trimethylamine-N-oxide (TMAO) in humans. J Nutr Biochem. 2017;45:77–82. doi:10.1016/j.jnutbio.2017.02.010
  11. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63. doi:10.1038/nature09922
  12. Geng J, Yang C, Wang B, et al. Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway. Biomed Pharmacother. 2018;97:941–947. doi:10.1016/j.biopha.2017.11.016
  13. Ma G, Pan B, Chen Y, et al. Trimethylamine N-oxide in atherogenesis: Impairing endothelial self-repair capacity and enhancing monocyte adhesion. Biosci Rep. 2017;37(2):BSR20160244. doi:10.1042/BSR20160244
  14. Seldin MM, Meng Y, Qi H, et al. Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κB. J Am Heart Assoc. 2016;5(2):e002767. doi:10.1161/JAHA.115.002767
  15. Chou RH, Chen CY, Chen IC, et al. Trimethylamine N-oxide, circulating endothelial progenitor cells, and endothelial function in patients with stable angina. Sci Rep. 2019;9(1):4249. doi:10.1038/s41598-019-40638-y
  16. Brunt VE, Gioscia-Ryan RA, Casso AG, et al. Trimethylamine-N-oxide promotes age-related vascular oxidative stress and endothelial dysfunction in mice and healthy humans. Hypertension. 2020;76(1):101–112. doi:10.1161/HYPERTENSIONAHA.120.14759
  17. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–585. doi:10.1038/nm.3145
  18. Zhu W, Gregory JC, Org E, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165(1):111–124. doi:10.1016/j.cell.2016.02.011
  19. Subramaniam S, Boukhlouf S, Fletcher C. A bacterial metabolite, trimethylamine N-oxide, disrupts the hemostasis balance in human primary endothelial cells but no coagulopathy in mice. Blood Coagul Fibrinolysis. 2019;30:324–330. doi:10.1097/MBC.0000000000000838
  20. Li Z, Wu Z, Yan J, et al. Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis. Lab Invest. 2019;99(3):346–357. doi:10.1038/s41374-018-0091-y
  21. Jin B, Ji F, Zuo A, et al. Destructive role of TMAO in T-tubule and excitation-contraction coupling in the adult cardiomyocytes. Int Heart J. 2020;61(2):355–363. doi:10.1536/ihj.19-372
  22. Oakley CI, Vallejo JA, Wang D, et al. Trimethylamine-N-oxide acutely increases cardiac muscle contractility. Am J Physiol Heart Circ Physiol. 2020;318(5):H1272–H1282. doi:10.1152/ajpheart.00507.2019
  23. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–1584. doi:10.1056/NEJMoa1109400
  24. Senthong V, Wang Z, Li XS, et al. Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: The contributory role of intestinal microbiota in a COURAGE-like patient cohort. J Am Heart Assoc. 2016;5(6):e002816. doi:10.1161/JAHA.115.002816
  25. Lee Y, Nemet I, Wang Z, et al. Longitudinal plasma measures of trimethylamine N-oxide and risk of atherosclerotic cardiovascular disease events in community-based older adults. J Am Heart Assoc. 2021;10(17):e020646. doi:10.1161/JAHA.120.020646
  26. Tang WHW, Li XS, Wu Y, et al. Plasma trimethylamine N-oxide (TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study. Am Heart J. 2021;236:80–86. doi:10.1016/j.ahj.2021.01.020
  27. Suzuki T, Heaney LM, Jones DJ, Ng LL. Trimethylamine N-oxide and risk stratification after acute myocardial infarction. Clin Chem. 2017;63(1):420–428. doi:10.1373/clinchem.2016.264853
  28. Matsuzawa Y, Nakahashi H, Konishi M, et al. Microbiota-derived trimethylamine N-oxide predicts cardiovascular risk after STEMI. Sci Rep. 2019;9(1):11647. doi:10.1038/s41598-019-48246-6
  29. Li XS, Obeid S, Klingenberg R, et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: A prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J. 2017;38(11):814–824. doi:10.1093/eurheartj/ehw582
  30. Sheng Z, Tan Y, Liu C, et al. Relation of circulating trimethylamine N-oxide with coronary atherosclerotic burden in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2019;123(6):894–898. doi:10.1016/j.amjcard.2018.12.018
  31. Senthong V, Li XS, Hudec T, et al. Plasma trimethylamine N-oxide, a gut microbe-generated phosphatidylcholine metabolite, is associated with atherosclerotic burden. J Am Coll Cardiol. 2016;67(22):2620–2628. doi:10.1016/j.jacc.2016.03.546
  32. Fu Q, Zhao M, Wang D, et al. Coronary plaque characterization assessed by optical coherence tomography and plasma trimethylamine-N-oxide levels in patients with coronary artery disease. Am J Cardiol. 2016;118(9):1311–1315. doi:10.1016/j.amjcard.2016.07.071
  33. Tan Y, Sheng Z, Zhou P, et al. Plasma trimethylamine N-oxide as a novel biomarker for plaque rupture in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2019;12(1):e007281. doi:10.1161/CIRCINTERVENTIONS.118.007281
  34. Ma R, Fu W, Zhang J, et al. TMAO: A potential mediator of clopidogrel resistance. Sci Rep. 2021;11(1):6580. doi:10.1038/s41598-021-85950-8
  35. Stubbs JR, House JA, Ocque AJ, et al. Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol. 2016;27(1):305–313. doi:10.1681/ASN.2014111063
  36. Al-Obaide MAI, Singh R, Datta P, et al. Gut microbiota-dependent trimethylamine-N-oxide and serum biomarkers in patients with T2DM and advanced CKD. J Clin Med. 2017;6(9):86. doi:10.3390/jcm6090086
  37. Tang WH, Wang Z, Fan Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: Refining the gut hypothesis. J Am Coll Cardiol. 2014;64(18):1908–1914. doi:10.1016/j.jacc.2014.02.617
  38. Trøseid M, Ueland T, Hov JR, et al. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure. J Intern Med. 2015;277(6):717–726. doi:10.1111/joim.12328
  39. Zhou X, Jin M, Liu L, et al. Trimethylamine N-oxide and cardiovascular outcomes in patients with chronic heart failure after myocardial infarction. ESC Heart Fail. 2020;7(1):188–193. doi:10.1002/ehf2.12552
  40. Schuett K, Kleber ME, Scharnagl H, et al. Trimethylamine-N-oxide and heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2017;70(25):3202–3204. doi:10.1016/j.jacc.2017.10.064
  41. Suzuki T, Heaney LM, Bhandari SS, et al. Trimethylamine N-oxide and prognosis in acute heart failure. Heart. 2016;102(11):841–848. doi:10.1136/heartjnl-2015-308826
  42. Israr MZ, Bernieh D, Salzano A, et al. Association of gut-related metabolites with outcome in acute heart failure. Am Heart J. 2021;234:71–80. doi:10.1016/j.ahj.2021.01.006
  43. Suzuki T, Yazaki Y, Voors AA, et al. Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: Results from BIOSTAT-CHF. Eur J Heart Fail. 2019;21(7):877–886. doi:10.1002/ejhf.1338
  44. Wei H, Zhao M, Huang M, et al. FMO3-TMAO axis modulates the clinical outcome in chronic heart-failure patients with reduced ejection fraction: Evidence from an Asian population [published online ahead of print on June 22, 2021]. Front Med. 2021. doi:10.1007/s11684-021-0857-2
  45. Li DY, Wang Z, Jia X, et al. Loop diuretics inhibit renal excretion of trimethylamine N-oxide. JACC Basic Transl Sci. 2021;6(2):103–115. doi:10.1016/j.jacbts.2020.11.010
  46. Gawałko M, Linz D, Dobrev D. Gut-microbiota derived TMAO: A risk factor, a mediator or a bystander in the pathogenesis of atrial fibrillation? Int J Cardiol Heart Vasc. 2021;34:100818. doi:10.1016/j.ijcha.2021.100818
  47. Svingen GFT, Zuo H, Ueland PM, et al. Increased plasma trimethylamine-N-oxide is associated with incident atrial fibrillation. Int J Cardiol. 2018;267:100–106. doi:10.1016/j.ijcard.2018.04.128
  48. Nguyen BO, Meems LMG, van Faassen M, et al. Gut-microbe derived TMAO and its association with more progressed forms of AF: Results from the AF-RISK study. Int J Cardiol Heart Vasc. 2021;34:100798. doi:10.1016/j.ijcha.2021.100798
  49. Gong D, Zhang L, Zhang Y, et al. Gut microbial metabolite trimethylamine N-oxide is related to thrombus formation in atrial fibrillation patients. Am J Med Sci. 2019;358(6):422–428. doi:10.1016/j.amjms.2019.09.002
  50. Heianza Y, Ma W, Manson JE, et al. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: A systematic review and meta-analysis of prospective studies. J Am Heart Assoc. 2017;6(7):e004947. doi:10.1161/JAHA.116.004947
  51. Schiattarella GG, Sannino A, Toscano E, et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: A systematic review and dose-response meta-analysis. Eur Heart J. 2017;38(39):2948–2956. doi:10.1093/eurheartj/ehx342
  52. Qi J, You T, Li J, et al. Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: A systematic review and meta-analysis of 11 prospective cohort studies. J Cell Mol Med. 2018;22(1):185–194. doi:10.1111/jcmm.13307
  53. Farhangi MA. Gut microbiota-dependent trimethylamine N-oxide and all-cause mortality: Findings from an updated systematic review and meta-analysis. Nutrition. 2020;78:110856. doi:10.1016/j.nut.2020.110856
  54. Li W, Huang A, Zhu H, et al. Gut microbiota-derived trimethylamine N-oxide is associated with poor prognosis in patients with heart failure. Med J Aust. 2020;213(8):374–379. doi:10.5694/mja2.50781
  55. Guasti L, Galliazzo S, Molaro M, et al. TMAO as a biomarker of cardiovascular events: A systematic review and meta-analysis. Intern Emerg Med. 2021;16(1):201–207. doi:10.1007/s11739-020-02470-5
  56. Li DY, Wang Z, Li XS, et al. Relationship between statin use and trimethylamine n-oxide in cardiovascular risk assessment. J Am Coll Cardiol. 2018;71(11):A115. doi:10.1016/s0735-1097(18)30656-9
  57. Zhu W, Wang Z, Tang WHW, Hazen SL. Gut microbe-generated trimethylamine N-oxide from dietary choline is prothrombotic in subjects. Circulation. 2017;135(17):1671–1673. doi:10.1161/CIRCULATIONAHA.116.025338
  58. Guasch-Ferré M, Hu FB, Ruiz-Canela M, et al. Plasma metabolites from choline pathway and risk of cardiovascular disease in the PREDIMED (Prevention With Mediterranean Diet) study. J Am Heart Assoc. 2017;6(11):e006524. doi:10.1161/JAHA.117.006524
  59. Pignanelli M, Just C, Bogiatzi C, et al. Mediterranean diet score: Associations with metabolic products of the intestinal microbiome, carotid plaque burden, and renal function. Nutrients. 2018;10(6):779. doi:10.3390/nu10060779
  60. Awoyemi A, Mayerhofer C, Felix AS, et al. Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial. EBioMedicine. 2021;70:103511. doi:10.1016/j.ebiom.2021.103511
  61. Boutagy NE, Neilson AP, Osterberg KL, et al. Probiotic supplementation and trimethylamine-N-oxide production following a high-fat diet. Obesity (Silver Spring). 2015;23(12):2357–2363. doi:10.1002/oby.21212
  62. Smits LP, Kootte RS, Levin E, et al. Effect of vegan fecal microbiota transplantation on carnitine- and choline-derived trimethylamine-N-oxide production and vascular inflammation in patients with metabolic syndrome. J Am Heart Assoc. 2018;7(7):e008342. doi:10.1161/JAHA.117.008342
  63. Trøseid M, Hov JR, Nestvold TK, et al. Major increase in microbiota-dependent proatherogenic metabolite TMAO one year after bariatric surgery. Metab Syndr Relat Disord. 2016;14(4):197–201. doi:10.1089/met.2015.0120
  64. Annunziata G, Maisto M, Schisano C, et al. Effects of grape pomace polyphenolic extract (Taurisolo®) in reducing TMAO serum levels in humans: Preliminary results from a randomized, placebo-controlled, cross-over study. Nutrients. 2019;11(1):139. doi:10.3390/nu11010139
  65. Dambrova M, Skapare-Makarova E, Konrade I, et al. Meldonium decreases the diet-increased plasma levels of trimethylamine N-oxide, a metabolite associated with atherosclerosis. J Clin Pharmacol. 2013;53(10):1095–1098. doi:10.1002/jcph.135
  66. Correlation of Intestinal Flora and Metabolomics in Patients With Ischemic Heart Failure. Accessed February 10, 2022.
  67. The Role of Gut Microbiota in Heart Failure and Pre-Heart Failure With Preserved Ejection Fraction. Accessed February 10, 2022.
  68. Impact of Time Restricted Eating on Patients With Coronary Artery Disease (CAD) Undergoing Cardiac Rehabilitation. Accessed February 10, 2022.